1. |
Russell WE, Van Wyk JJ, Pledger WJ. Inhibition of the mitogenic effects of plasma by a monoclonal antibody to somatomedin C [J]. Proc Natl Acad Sci USA, 1984; 81(8)∶2389.
|
2. |
Blakesley VA, Koval AP, Stannard BS, et al. Replacement of tyrosine 1251 in the carboxyl terminus of the insulin-like growth factor-Ⅰ receptor disrupts the actin cytoskeleton and inhibits proliferation and anchorage-independent growth [J]. J Biol Chem, 1998; 273(29)∶18411.
|
3. |
Valentinis B, Baserga R. IGF-Ⅰ receptor signalling in transformation and differentiation [J]. Mol Pathol, 2001; 54(3)∶133.
|
4. |
Hellawell GO, Turner GD, Davies DR, et al. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease [J]. Cancer Res, 2002; 62(10)∶2942.
|
5. |
Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells [J]. Science, 2002; 296(5567)∶550.
|
6. |
牛坚, 钱海鑫, 李向农, 等. RNA干涉胰岛素样生长因子1类受体的研究 [J]. 中华实验外科杂志, 2006; 23(7)∶872.
|
7. |
Sachdev D, Li SL, Hartell JS, et al. A chimeric humanized single-chain antibody against the type Ⅰ insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-Ⅰ [J]. Cancer Res, 2003; 63(3)∶627.
|
8. |
Andrews DW, Resnicoff M, Flanders AE, et al. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type Ⅰ receptor in malignant astrocytomas [J]. J Clin Oncol, 2001; 19(8)∶2189.
|
9. |
Moschos SJ, Mantzoros CS. The role of the IGF system in cancer: from basic to clinical studies and clinical applications [J]. Oncology, 2002; 63(4)∶317.
|
10. |
Sell C, Dumenil G, Deveaud C, et al. Effect of a null mutation of the insulin-like growth factor Ⅰ receptor gene on growth and transformation of mouse embryo fibroblasts [J]. Mol Cell Biol, 1994; 14(6)∶3604.
|
11. |
Werner H. Dysregulation of the type 1 IGF receptor as a paradigm in tumor progression [J]. Mol Cell Endocrinol, 1998; 141(1-2)∶1.
|
12. |
Borkhardt A. Blocking oncogenes in malignant cells by RNA interference——new hope for a highly specific cancer treatment? [J]. Cancer Cell, 2002; 2(3)∶167.
|
13. |
Camirand A, Lu Y, Pollak M. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells [J]. Med Sci Monit, 2002; 8(12)∶BR521.
|
14. |
Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans [J]. Nature, 1998; 391(6669)∶806.
|
15. |
吕伟, 张超. RNAi 在大肠癌基因治疗中的应用策略和展望 [J]. 中国普外基础与临床杂志, 2005; 12(6)∶637.
|
16. |
陈华, 景在平, 包俊敏, 等. RNA干扰对兔血管平滑肌细胞bcl2基因表达的影响 [J]. 中国普外基础与临床杂志, 2007; 14(1)∶56.
|
17. |
Baserga R. The insulin-like growth factor Ⅰ receptor: a key to tumor growth? [J]. Cancer Res, 1995; 55(2)∶249.
|
18. |
Valentinis B, Baserga R. IGF-Ⅰ receptor signalling in transformation and differentiation [J]. Mol Pathol, 2001; 54(3)∶133.
|
19. |
Liu X, Turbyville T, Fritz A, et al. Inhibition of insulin-like growth factor Ⅰ receptor expression in neuroblastoma cells induces the regression of established tumors in mice [J]. Cancer Res, 1998; 58(23)∶5432.
|